Loading stock data…
BMY
$56.41+0.85 (+1.53%)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bristol-Myers Squibb Company in the Healthcare sector is trading at $56.41. Wall Street consensus targets $63.08 (25 analysts), implying a +11.8% move over the next 12 months. The stock is currently 10% below its 52-week high of $62.89, remaining 7.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$56.41
Potential Downside
0%
Whystock Fair Value$56.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Hold
Mean target$63.08+11.8%
Range$40.00 – $75.00
Fundamentals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
4.43%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.25%
Volume
Today's trading volume
8.58M
Recent News
Earn $5,000+ Yearly With These 4 Dividend Stocks
Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfolio pays you on a schedule independent of whether you showed up to work or whether your employer hit its quarter. Real ... Earn $5,000+ Yearly With These 4 Dividend Stocks
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced […]
Inside Bristol Myers’ AI-powered procurement overhaul
The pharmaceutical giant cut procurement timelines from months to weeks while challenging conventional wisdom on AI data readiness.
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Can MariTide Save Amgen Stock From Its Fading Blockbusters?
The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.